Sanofi Diabetes
YOU ARE HERE
Apidra® insulin glulisine [rDNA origin] injection
For U.S. Residents Only
Start saving on Apidra® through our Mealtime Masters Program! Learn more >>

Say hello to Apidra®—to help you with your blood sugar control at mealtime.

Have you received an Apidra® insulin prescription? Congratulations! You are officially on your way helping to manage your blood sugar at mealtime.

Apidra® is the only mealtime insulin approved for you to take within 15 minutes before or within 20 minutes after starting a meal.

Still getting used to your Apidra® routine? Here are some tips for staying on track.


Remember your dose will change from meal to meal based on what and how much you eat. Talk with your healthcare professional about the Apidra® dose that's right for you. Your dose will be based on what your body needs, your lifestyle, how much you exercise, your diet, and the other medications you take.


After you dose and eat (or the other way around), check your blood sugar and keep a daily log of your levels. This will help you and your healthcare professional see what works and what doesn't.


If you have any questions about your insulin dose, talk to your healthcare professional right away. If mealtime insulin is new to you, it may take some time to get used to it, and that's okay.

 

If you are taking Apidra®, you can receive a personalized training session from one of our Certified Diabetes Educators (CDE)**. Learn more about our CDEs and get No Co-Pay* on Apidra® through the Mealtime Masters Program. Certain exclusions and restrictions apply.

Are you using Apidra® with a vial and syringe?

Watch this instructional step-by-step injection video about how to take Apidra®.

Are you using the Apidra® SoloSTAR® Pen?

Check out this step-by-step guide about how to use the pen. It'll help you become a pro in no time.



Before beginning, check the label on the insulin
pen to ensure you are using the correct insulin.
Keep the needle straight as you attach it.
Apidra® SoloSTAR® uses push-on or screw-on
needles.
This removes air bubbles and ensures that the pen
and needle are working properly. Select a dose of 2 units.

Always perform the safety test before each injection.

Take off the outer needle cap and keep it to remove
the used needle after your injection. Then take off the inner
needle cap and discard it.
Continue
Hold the pen with the needle pointing upward. Tap the
reservoir gently so any air bubbles rise up to the needle.

Press the injection button all the way in. Check if insulin
comes out of the needle. If insulin does not come out,
check for air bubbles and repeat the test 2 more times to
remove them. If no insulin comes out after the third time,
try again with a new needle.
Be sure the dose window shows “0” following the
safety test. Select your required dose in 1-unit steps.
If you need a dose larger than 80 units, use 2 or more
injections. (This example shows 30 units.)
Using the method your healthcare professional
showed you, insert the needle into the skin in
either your upper arm, abdomen (stomach area),
or thigh (upper leg). Press the injection button in
all the way. Hold the button in that position. Slowly
count to 10, then withdraw the needle.
10 secs
Always remove the needle after each injection. Put the
outer needle cap back on the needle and use it to
unscrew the needle from the pen. Dispose of the needle
safely, as instructed by your healthcare provider (eg, in a
sharps container). Put the cap on the pen.

If you can’t dial to the dose you want, check to see if you have enough insulin in the reservoir.

If you have any other problems with the pen, first try changing the needle and repeating the safety test.

Each Apidra® SoloSTAR® is for use by one person only.

You should carefully read the instruction leaflet that comes with your pen for additional important information.

Prescription Apidra® is for adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes to improve blood sugar control. Apidra® given by subcutaneous injection is usually used with a longer-acting insulin. When used as a mealtime insulin, Apidra® should be given within 15 minutes before or within 20 minutes after starting a meal.

Apidra® may be infused subcutaneously by external insulin infusion pumps.

Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection)

Do not use Apidra® during a low blood sugar reaction (hypoglycemia) or if you are allergic to any of the ingredients in Apidra®.

Do not share needles, insulin pens or syringes with others. Do NOT reuse needles.

You must test your blood sugar levels while using insulin, such as Apidra®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Apidra® must only be used if the solution is clear and colorless with no particles visible.

Please click here for additional Important Safety Information for Apidra®.

Please click here for Full Prescribing Information for Apidra®.

A Flash player is required to view this video. Download the latest Flash Plug-in here.

Get Adobe Flash player

Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection)

Do not use Apidra® during a low blood sugar reaction (hypoglycemia) or if you are allergic to any of the ingredients in Apidra®.

Do not share needles, insulin pens or syringes with others. Do NOT reuse needles.

You must test your blood sugar levels while using insulin, such as Apidra®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Apidra® must only be used if the solution is clear and colorless with no particles visible.

Apidra®, when given by injection under the skin, should not be mixed with insulins other than NPH. Do not mix Apidra® with any insulin when used in the pump or for intravenous administration.

The most common side effect of insulin, including Apidra®, is low blood sugar (hypoglycemia), which may be serious. Some people may experience symptoms such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia may be serious and life threatening. It may cause harm to your heart or brain. Other possible side effects may include low blood potassium, injection site reactions, such as changes in fat tissue at the injection site, and allergic reactions, such as itching and rash. Less common, but potentially more serious or life-threatening, is generalized allergy to insulin, including anaphylactic reactions.

Tell your doctor about other medicines, especially ones commonly called TZDs (thiazolidinediones), and supplements you are taking because they can change the way insulin works. Before starting Apidra®, tell your doctor about all your medical conditions including if you have liver or kidney problems, are pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed. If you have heart failure or other heart problems, it may get worse while you take TZDs with Apidra®.

It is important to always follow the instructions provided with your Apidra® prescription for use with an external insulin infusion pump. These instructions may differ from the instructions that accompany your insulin infusion pump. Failure to follow the Apidra® specific instructions may lead to serious side effects.

You must change the infusion set (reservoir, tubing, and catheter), and the Apidra® in the pump reservoir at least every 48 hours. Do not mix Apidra® with any insulin when used in the pump and do not dilute Apidra®.

If the pump or infusion set does not work right or in case of handling errors, you may not get the right amount of insulin. This can cause low blood sugar (hypoglycemia), high blood sugar (hyperglycemia), high amounts of sugar and ketones in your blood (ketosis) or a build-up of acid in your blood because your body is breaking down fat instead of sugar (diabetic ketoacidosis). It is important to have another way to inject Apidra® in case the pump does not work.

Apidra® has not been studied in children with type 2 diabetes or in children younger than 4 years of age with type 1 diabetes. In a clinical study of children with type 1 diabetes, there was a higher rate of severe symptomatic hypoglycemia in the two treatment groups (Apidra® or insulin lispro) compared to adult trials with type 1 diabetes.

Apidra® SoloSTAR® is a disposable prefilled insulin pen. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen.

Indications and Usage for Apidra® (insulin glulisine [rDNA origin] injection)


Prescription Apidra® is for adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes to improve blood sugar control. Apidra® given by subcutaneous injection is usually used with a longer-acting insulin. When used as a mealtime insulin, Apidra® should be given within 15 minutes before or within 20 minutes after starting a meal.

Apidra® may be infused subcutaneously by external insulin infusion pumps.

Click here for Full Prescribing Information for Apidra®.

Click here for information on Sharps Medical Waste Disposal.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.



The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

*Offer is not valid for patients if their prescriptions are paid in part or full by any state or federally funded programs, including, but not limited to, Medicare or Medicaid, Medigap, VA, DOD, or TriCare. Offer is not valid where prohibited by law. Sanofi US reserves the right to rescind, revoke, or amend this offer without notice. Maximum benefit is $100 off per prescription depending on your out of pocket costs for the duration of the program.

**"Certified Diabetes Educator" and "CDE" are certification marks owned and registered by the National Certification Board for Diabetes Educators (NCBDE). NCBDE is not affiliated in any way with Sanofi US (or your official designation). NCBDE does not sponsor or endorse any diabetes-related products or services.